FindTrial
Sign In

Clinical study of a novel molecular marker based on plasma diagnosis of rars-mad1l1 fusion gene

Clinical study of a novel molecular marker based on plasma diagnosis of rars-mad1l1 fusion gene

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040321
Enrollment
Unknown
Registered
2020-11-27
Start date
2020-11-19
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Gold Standard:Fluorescence in situ hybridization in tumor tissue
Index test:detection&#32
of&#32
F-CircRM&#32
in&#32
plasma

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with nasopharyngeal carcinoma confirmed by pathology in our hospital; 2. KPS score >=70; 3. Aged older than 18 years old; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. At the same time, there were other organs and other types of malignant tumors; 2. There were serious heart, lung and kidney diseases; 3. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Expression of circular RNA f-circrm;—

Countries

China

Contacts

Public ContactGou Qiheng

West China Hospital, Sichuan University

douglasgou@foxmail.com+86 13551835272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026